Licensed Product-Related Regulatory Interactions. From and after the Research Completion Date, as between the Parties, Lilly shall be solely responsible for any communications with any Regulatory Authorities regarding the Licensed Products. In the event that Sigilon receives any communication from a Regulatory Authority following the Research Completion Date, Sigilon shall refer such Regulatory Authority to Lilly and shall not otherwise communicate with such Regulatory Authority without Lilly’s prior written consent.
Appears in 2 contracts
Sources: Research Collaboration and Exclusive License Agreement (Sigilon Therapeutics, Inc.), Research Collaboration and Exclusive License Agreement (Sigilon Therapeutics, Inc.)